{"id":"W2789498468","doi":"10.1007/s40258-018-0371-0","title":"Policy Options for Infliximab Biosimilars in Inflammatory Bowel Disease Given Emerging Evidence for Switching","year":2018,"lang":"en","type":"letter","venue":"Applied Health Economics and Health Policy","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":9,"is_retracted":false,"has_abstract":true,"ca_institutions":"Robarts Clinical Trials; Western University; University of Ottawa","funders":"Janssen Pharmaceuticals","keywords":"Biosimilar; Infliximab; Inflammatory bowel disease; Medicine; Incentive; Intensive care medicine; Payment; Health economics; Public economics; Risk analysis (engineering); Disease; Business; Public health; Economics; Finance","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01011034,0.000443198,0.0006980311,0.000673547,0.003090645,0.006146542,0.001752978,0.06327397,0.007032476],"category_scores_gemma":[0.05418876,0.0004379447,0.001119001,0.0007623628,0.005264374,0.006034921,0.002538306,0.0355527,0.003139524],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00653872,"about_ca_system_score_gemma":0.006035113,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002176275,"about_ca_topic_score_gemma":0.003372493,"domain_scores_codex":[0.9906487,0.003887745,0.001155565,0.0008872218,0.002470372,0.000950401],"domain_scores_gemma":[0.9749838,0.01859823,0.001505241,0.0006678854,0.002441448,0.001803404],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001689299,0.0001672555,0.001433333,0.0002149146,0.00002158531,0.0103792,0.0009000871,0.001056619,0.001151283,0.1288819,0.7983047,0.05732007],"study_design_scores_gemma":[0.0001768435,0.0001116062,0.0008789258,0.0008856762,0.00002144903,0.005991196,0.0008495277,0.001869212,0.0005412941,0.1256683,0.8629398,0.00006629563],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"commentary","genre_scores_codex":[0.0005442804,0.001163633,0.000313086,0.9927159,0.001942121,0.000008520694,0.000008463857,0.00001264986,0.00329129],"genre_scores_gemma":[0.0164853,0.001685538,0.001038937,0.9584796,0.01953818,0.00003758094,0.00001540029,0.00001788306,0.002701455],"genre_candidate":"commentary","genre_consensus":"commentary","teacher_disagreement_score":0.06327397,"threshold_uncertainty_score":0.0534693,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09600940158023422,"score_gpt":0.4134414470554328,"score_spread":0.3174320454751987,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}